Genetically targeted clinical trials in parkinson’s disease: Learning from the successes made in oncology

Magnus Sjögren*, Henri J. Huttunen, Per Svenningsson, Håkan Widner

*Corresponding author af dette arbejde
2 Citationer (Scopus)

Abstract

Clinical trials in neurodegenerative disorders have been associated with high rate of failures, while in oncology, the implementation of precision medicine and focus on genetically defined subtypes of disease and targets for drug development have seen an unprecedented success. With more than 20 genes associated with Parkinson’s disease (PD), most of which are highly penetrant and often cause early onset or atypical signs and symptoms, and an increasing understanding of the associated pathophysiology culminating in dopaminergic neurodegeneration, applying the technologies and designs into the field of neurodegeneration seems a logical step. This review describes some of the methods used in oncology clinical trials and some attempts in Parkinson’s disease and the potential of further implementing genetics, biomarkers and smart clinical trial designs in this disease area.

OriginalsprogEngelsk
Artikelnummer1529
TidsskriftGenes
Vol/bind12
Udgave nummer10
Sider (fra-til)1-8
Antal sider8
ISSN2073-4425
DOI
StatusUdgivet - 28 sep. 2021
Udgivet eksterntJa

Fingeraftryk

Dyk ned i forskningsemnerne om 'Genetically targeted clinical trials in parkinson’s disease: Learning from the successes made in oncology'. Sammen danner de et unikt fingeraftryk.

Citationsformater